Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
104 hedge funds and large institutions have $52.4M invested in Eagle Pharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 25 reducing their positions, and 26 closing their positions.
800% more call options, than puts
Call options by funds: $522K | Put options by funds: $58K
68% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 25
2.12% less ownership
Funds ownership: 79.27% → 77.15% (-2.1%)
3% less funds holding
Funds holding: 107 → 104 (-3)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
68% less capital invested
Capital invested by funds: $163M → $52.4M (-$110M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$2.43M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.08M |
| 3 |
Two Sigma Advisers
New York
|
+$1.97M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.8M |
| 5 |
Two Sigma Investments
New York
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.88M |
| 2 |
SGCIA
Smith Graham & Co Investment Advisors
Houston,
Texas
|
-$4.31M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$3.84M |
| 4 |
Janus Henderson Group
London,
|
-$3.61M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.29M |
EGRX Hedge Fund Activity: Q4 2023 in Review
104 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2023, worth a combined $52.4M — down 68% from $163M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of EGRX and 23 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 42 added.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $2.43M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $7.88M sold.
- 104 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2023, down from 107 in Q3 2023.
- Funds reported $52.4M of Eagle Pharmaceuticals, Inc. stock for Q4 2023, down 68% quarter-over-quarter.
- 23 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2023 and 26 closed out, a net change of -3 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2023 was J. Goldman & Co, an estimated $2.43M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2023 was Adage Capital Partners, an estimated $7.88M sold.
Based on aggregated 13F filings for Q4 2023.